Literature DB >> 24573631

Management of metastatic spinal column neoplasms--an update.

João Luiz Vitorino Araujo, José Carlos Esteves Veiga, Eberval Gadelha Figueiredo, Victor Rosseto Barboza, Jefferson Walter Daniel, Alexandros Theodoros Panagopoulos.   

Abstract

The increased survival of cancer patients due to the improvement and advancement of therapeutic modalities has promoted progressive increase in the prevalence of metastatic tumors of the spine, making it important for healthcare professionals to acquire knowledge in the field. Spinal column metastases are usually secondary to malignant neoplasm of the breast, lung and prostate, male gender being the most often affected and pain being the initial symptom in 90% of patients. It is estimated that 30-90% of terminally ill patients with cancer have metastases at some spinal column segment. Clinical history, physical and neurological assessments are critical to determine the degree and extent of the lesion, and therefore choose the appropriate imaging method to be requested. This study aims to perform a review and didactic description of the main aspects related to the physiopathology, diagnosis and treatment of this disease.

Entities:  

Mesh:

Year:  2013        PMID: 24573631     DOI: 10.1590/s0100-69912013000600015

Source DB:  PubMed          Journal:  Rev Col Bras Cir        ISSN: 0100-6991


  3 in total

1.  Prognostic parameters and spinal metastases: a research study.

Authors:  Jefferson W Daniel; José C E Veiga
Journal:  PLoS One       Date:  2014-10-13       Impact factor: 3.240

2.  Evaluate the characteristics and clinical significance of "toxic twin-leaf" sign in spinal epidural metastases before percutaneous vertebroplasty.

Authors:  Xiqi Sun; Qinghua Tian; Chungen Wu; Yongde Cheng
Journal:  J Interv Med       Date:  2020-03-30

3.  Kyphoplasty in the treatment of occult and non-occult metastatic vertebral tumors.

Authors:  Shuangjun He; Zhangzhe Zhou; Changhao Zhang; Nanning Lv; Zhonglai Qian; Zhiyong Sun
Journal:  Medicine (Baltimore)       Date:  2020-06-19       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.